Troxacitabine prodrugs for pancreatic cancer

Nucleosides, Nucleotides and Nucleic Acids

Volumn 26, Issue 8-9, 2007, Pages 1073-1077

  Adema, A D ^a   Radi, M ^b   Daft, J ^b   Narayanasamy, J ^a   Hoebe, E K ^a   Alexander, L E ^b   Chu, C K ^b   Peters, G J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF GEORGIA   (United States)

Author keywords

Lipophilic prodrugs; Pancreatic cancer; Troxacitabine

Indexed keywords

PRODRUG; TROXACITABINE;

ARTICLE; CONTROLLED STUDY; DRUG RETENTION; DRUG SYNTHESIS; DRUG UPTAKE; HUMAN; HUMAN CELL; LIPOPHILICITY; PANCREAS CANCER; SENSITIVITY ANALYSIS;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CYTOSINE; DIOXOLANES; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; PANCREATIC NEOPLASMS; PRODRUGS;

EID: 36849014282     PISSN: 15257770     EISSN: 15322335     Source Type: Journal    
DOI: 10.1080/15257770701515591     Document Type: Article

References (16)

1. Grove, K.L.; Guo, X.; Liu, S.H.; Gao, Z.; Chu, C.K.; Cheng, Y.C. Anticancer activity of beta-L-dioxolane-cytidine, a novel nucleoside analogue with the unnatural L configuration. Cancer Res. 1995, 55, 3008-3011.
2. Gourdeau, H.; Jolivet, J. Troxacitabine (Troxatyl™) a deoxycytidine nucleoside analog with potent antitumor activity; In Cancer Drug Discovery and Developement: Deoxynucleoside Analogs in Cancer Therapy, ed. Peters, G.J., Humana Press Inc., Totowa, NJ; 2006, pp. 199-214.
3. Gumina, G.; Chong, Y.; Chu, C.K. L-Nucleosides as chemotherapeutic agents; In Cancer Drug Discovery and Developement: Deoxynucleoside Analogs in Cancer Therapy, ed. Peters, G.J., Humana Press Inc., Totowa, NJ; 2006, pp. 173-198.
4. Gourdeau, H.; Clarke, M.L.; Ouellet, F.; Mowles, D.; Selner, M.; Richard, A.; Lee, N.; Mackey, J.R.; Young, J.D.; Jolivet, J.; Lafreniere, R.G.; Cass, C.E. Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines. Cancer Res. 2001, 61, 7217-7224.
5. Kukhanova, M.; Liu, S.H.; Mozzherin, D.; Lin, T.S.; Chu, C.K.; Cheng, Y.C. L- and D-enantiomers of 2′,3′-dideoxycytidine 5′-triphosphate analogs as substrates for human DNA polymerases. Implications for the mechanism of toxicity. J. Biol. Chem. 1995, 270, 23055-23059.
6. Chou, K.M.; Kukhanova, M.; Cheng, Y.C. A novel action of human apurinic/apyrimidinic endonuclease: Excision of L-configuration deoxyribonucleoside analogs from the 3′ termini of DNA. J. Biol. Chem. 2000, 275, 31009-31015.
7. Chou, K.M.; Cheng, Y.C. The exonuclease activity of human apurinic/apyrimidinic endonuclease (APE1). Biochemical properties and inhibition by the natural dinucleotide Gp4G. J. Biol. Chem. 2003, 278, 18289-18296.
8. Weitman, S.; Marty, J.; Jolivet, J.; Locas, C.; Von Hoff, D.D. The new dioxolane, (-)-2′-deoxy-3′-oxacytidine (BCH-4556, troxacitabine), has activity against pancreatic human tumor xenografts. Clin. Cancer Res. 2000, 6, 1574-1578.
9. Lapointe, R.; Letourneau, R.; Steward, W.; Hawkins, R.E.; Batist, G.; Vincent, M.; Whittom, R.; Eatock, M.; Jolivet, J.; Moore, M. Phase II study of troxacitabine in chemotherapy-naive patients with advanced cancer of the pancreas: Gastrointestinal tumors. Ann. Oncol. 2005, 16, 289-293.
10. de Bono, J.S.; Stephenson, J., Jr.; Baker, S.D.; Hidalgo, M.; Patnaik, A.; Hammond, L.A.; Weiss, G.; Goetz, A.; Siu, L.; Simmons, C.; Jolivet, J.; Rowinsky, E.K. Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: A phase I and pharmacokinetic study in patients with advanced solid malignancies. J. Clin. Oncol. 2002, 20, 96-109.
11. Kim, H.O.; Schinazi, R.F.; Nampalli, S.; Shanmuganathan, K.; Cannon, D.L.; Alves, A.J.; Jeong, L.S.; Beach, J.W.; Chu, C.K. 1,3-dioxolanylpurine nucleosides (2R,4R) and (2R,4S) with selective anti-HIV-1 activity in human lymphocytes. J. Med. Chem. 1993, 36, 30-37.
12. Keepers, Y.P.; Pizao, P.E.; Peters, G.J.; Ark-Otte, J.; Winograd, B.; Pinedo, H.M. Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing. Eur. J. Cancer 1991, 27, 897-900.
13. Radi, M.; Adema, A.D.; Daft, J.R.; Cho, J.H.; Hoebe, E.K.; Alexander, L.E.; Peters, J.; Chu, C.K. In vitro optimization of non-small cell lung cancer activity with troxacitabine, L-1,3-dioxolane-cytidine prodrugs. J. Med. Chem. 2007, 50, 2249-2253.
14. Bergman, A.M.; Kuiper, C.M.; Voorn, D.A.; Comijn, E.M.; Myhren, F.; Sandvold, M.L.; Hendriks, H.R.; Peters, G.J. Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinofuranosylcytosine in leukemia and solid tumor cell lines. Biochem. Pharmacol. 2004, 67, 503-511.
15. Koller-Lucae, S.K.; Suter, M.J.; Rentsch, K.M.; Schott, H.; Schwendener, R.A. Metabolism of the new liposomal anticancer drug N4-octadecyl-1-beta-D- arabinofuranosylcytosine in mice. Drug Metab Dispos. 1999, 27, 342-350.
16. Hamilton, J.A. Fast flip-flop of cholesterol and fatty acids inmembranes: Implications for membrane transport proteins. Curr. Opin. Lipidol. 2003, 14, 263-271.